A Phase 2 interventional study of Technosphere® Insulin Inhalation Powder and Technosphere Insulin® Inhalation Powder in Diabetes Mellitus: Type 1, sponsored by Mannkind Corporation. Completed at 2 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-10-16.
Sponsored by Mannkind Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 1.
Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, this one is the 24th largest by enrollment, is one of 3 that started in 2008, is one of 8 in phase 2, and was the 19th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →1 of the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:
Mannkind Corporation · Sites in United States
Ages 6–17
By country, each count listing its studies:
Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 17 · Phase 4 4
First in 1989; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 74 across the 35 interventional studies. Of the 34 that completed or were terminated, 10 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 35 have an industry lead sponsor. The 10 most frequent:
Mannkind Corporation is the lead sponsor of 57 studies on the registry; 3 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation: 1 open now, 1 under way, none of them phase 3. Of 19 finished, 10 (53%) have results posted.
Among the 21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation, this one is the 13th largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2008, is one of 5 in phase 2, and was the 6th registered.
Mannkind Corporation’s Diabetes Mellitus, Type 1 studies by the year they started, since 2005.
1 of the studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07224321Mannkind CorporationINHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Mannkind Corporation’s 21 in Diabetes Mellitus, Type 1:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
28 subjects to be enrolled for a screening period, 3 dosing visits \& a follow-up visit. Visits 2 and 3 dosing of TI Inhalation Powder, cross over between two 15 U cartridges and one 30 U cartridge. Visit 4 dosing will be a sc injection of 10 IU of RAA (rapid-acting insulin analogue).
28 eligible subjects were planned to be enrolled to determine bioequivalence and safety parameters of two 15 U TI Inhalation Powder cartridges versus one 30 U TI Inhalation Powder cartridge, according to a randomized, 2-way crossover design. Additionally, bioavailability of one 30 U TI Inhalation Powder cartridge to a single subcutaneous injection of 10 IU of RAA will be compared.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Males and Females > 18 and \< 60 years of age Clinical diagnosis of type 1 diabetes mellitus with stable anti-diabetic regimen for at least 90 days prior to Screening of \< 30 kg/m2 Non-smokers (never smoked or former smokers (> 6 months since cessation) Pulmonary Function Testing ( > 70%, FEV1/FVC > 70%, TLC > 80% DLco [unc] > 70% of Predicted Written
Exclusion Criteria:
Two or more severe hypoglycemic episodes within 6 months of Screening/Visit 1 Severe complications of diabetes Previous exposure to any inhaled insulin product other than TI inhalation Powder or similar formulation Inability to perform PFT maneuvers meeting recommended American Thoracic Society (ATS) standards of acceptability and repeatability criteria Respiratory tract infection within 8 weeks prior to Screening/Visit 1 History of (COPD), clinically proven asthma, and/or any other pulmonary disease (eg. Obstructive sleep apnea), confirmed by pulmonary function testing, and/or radiologic findings Major organ system diseases including seizures, heart failure, uncontrolled hypertension, cancer within the past 5 years, liver disease, anemia or disorder Clinically significant abnormalities on screening laboratory evaluation Female subjects who are pregnant, lactating, or planning to become pregnant during the clinical trial period or not practicing adequate Unable and/or unlikely to comprehend how to use the device in this study or to follow study instructions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Technosphere® Insulin Inhalation Powder, two 15 U cartridges
Drug: Technosphere® Insulin Inhalation Powder
Technosphere® Insulin Inhalation Powder, one 30 U cartridge
Drug: Technosphere Insulin® Inhalation Powder
Rapid Acting Analogue subjects received 10 IU sc Insulin Lispro
Drug: RAA Population
TI Inhalation Powder, two 15 U cartridges
TI Inhalation Powder, one 30 U cartridge
RAA Population: All subjects received a single 10 IU sc injection of insulin lispro.
Bioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin AUC0-360
Dose-normalized baseline-corrected area under the serum insulin vs. time curve
Time frame: 0 to 360 minutes post-dose
Bioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin Cmax.
Maximum observed baseline-corrected serum insulin concentration
Time frame: 0 to 360 minutes post-dose
Bioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin Tmax
Time frame: 0 to 360 minutes post-dose
Relative Bioavailability of 30 U of TI (TI Inhalation Powder B) Versus 10 U of sc Insulin Lispro
Dose-normalized baseline-corrected area under the serum insulin vs. time curve (time 0 to 360 minutes post-dose)
Time frame: 0 to 360 minutes post-dose
This was a single site with first subject screened 24 Apr 2008
| Milestone | TI - A (2x15 U)/TI - B (1x30 U)/10 U sc Insulin Lispro | TI - B (1x30 U)/TI - A (2x15 U)/10 U sc Insulin Lispro |
|---|---|---|
| Started | 13 | 16 |
| Completed | 13 | 16 |
| Not completed | 0 | 0 |
| Milestone | TI - A (2x15 U)/TI - B (1x30 U)/10 U sc Insulin Lispro | TI - B (1x30 U)/TI - A (2x15 U)/10 U sc Insulin Lispro |
|---|---|---|
| Started | 13 | 16 |
| Completed | 13 | 14 |
| Not completed | 0 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | TI - A (2x15 U)/TI - B (1x30 U)/10 U sc Insulin Lispro | TI - B (1x30 U)/TI - A (2x15 U)/10 U sc Insulin Lispro |
|---|---|---|
| Started | 13 | 14 |
| Completed | 13 | 14 |
| Not completed | 0 | 0 |
| Milestone | TI - A (2x15 U)/TI - B (1x30 U)/10 U sc Insulin Lispro | TI - B (1x30 U)/TI - A (2x15 U)/10 U sc Insulin Lispro |
|---|---|---|
| Started | 13 | 14 |
| Completed | 12 | 14 |
| Not completed | 1 | 0 |
| Withdrew: Cannot use clamp data | 1 | 0 |
| Milestone | TI - A (2x15 U)/TI - B (1x30 U)/10 U sc Insulin Lispro | TI - B (1x30 U)/TI - A (2x15 U)/10 U sc Insulin Lispro |
|---|---|---|
| Started | 12 | 14 |
| Completed | 12 | 14 |
| Not completed | 0 | 0 |
Dose-normalized baseline-corrected area under the serum insulin vs. time curve
| (micro U)*min/mL | Techosphere Insulin - A (2 x 15 U) | Techosphere Insulin - B (1 x 30 U) |
|---|---|---|
| Bioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin AUC0-360 | 3337.2 ± 1.096 | 3396.6 ± 1.096 |
Maximum observed baseline-corrected serum insulin concentration
| (micro U)/mL | Techosphere Insulin - A (2 x 15 U) | Techosphere Insulin - B (1 x 30 U) |
|---|---|---|
| Bioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin Cmax. | 65.72 ± 1.098 | 69.08 ± 1.098 |
| min | Techosphere Insulin - A (2 x 15 U) | Techosphere Insulin - B (1 x 30 U) |
|---|---|---|
| Bioequivalence of Two 15 U Cartridges (TI Inhalation Powder A) and One 30 U Cartridge (TI Inhalation Powder B) Based on Baseline Corrected Insulin Tmax | 10 (5 to 24) | 10 (5 to 20) |
Dose-normalized baseline-corrected area under the serum insulin vs. time curve (time 0 to 360 minutes post-dose)
| (micro U)*min/mL | Techosphere Insulin - B (1 x 30 U) | 10 U Subcutaneous (sc) Insulin Lispro |
|---|---|---|
| Relative Bioavailability of 30 U of TI (TI Inhalation Powder B) Versus 10 U of sc Insulin Lispro | 3406.8 ± 1.095 | 7404.0 ± 1.102 |
Collected over From time of first dose to 30d after last dose; Serious adverse event (SAE) = until resolution. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Techosphere Insulin - A (2 x 15 U) | — | 0/27 (0%) | 9/27 (33.3%) |
| Techosphere Insulin - B (1 x 30 U) | — | 0/29 (0%) | 14/29 (48.3%) |
| 10 U Subcutaneous (sc) Insulin Lispro | — | 0/26 (0%) | 5/26 (19.2%) |
| Event | Techosphere Insulin - A (2 x 15 U) | Techosphere Insulin - B (1 x 30 U) | 10 U Subcutaneous (sc) Insulin Lispro |
|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 4/27 | 7/29 | 0/26 |
| HeadacheNervous system disorders | 2/27 | 5/29 | 1/26 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/27 | 4/29 | 1/26 |
| Hepatic enzyme increasedInvestigations | 0/27 | 0/29 | 2/26 |
| NauseaGastrointestinal disorders | 2/27 | 1/29 | 1/26 |
| Age, Continuous(years) | Safety Population |
|---|---|
| Mean | 37.4 ± 12.71 |
| Sex: Female, Male(Participants) | Safety Population |
|---|---|
| Female | 10 |
| Male | 19 |
| Body mass index (BMI)(kg/m squared) | Safety Population |
|---|---|
| Mean | 26.61 ± 2.772 |
The record gives a start of Apr 2008, a primary completion of Nov 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 5 years 11 months after primary completion. A results delay was requested in Jun 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin, Regular, Human